BRIEF-Fda Accepts Biologics License Application For Fremanezumab With Priority Review
December 18, 2017 at 08:20 AM EST
* FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR FREMANEZUMAB WITH PRIORITY REVIEW FOR PREVENTION OF MIGRAINE AND GRANTS FAST TRACK DESIGNATION FOR CLUSTER HEADACHE DEVELOPMENT PROGRAM
